Case Studies

Understanding payer willingness to pay for a novel dermatologic therapy

26/04/2023

Author:

Sarah Bailey
About the Author

Article Tags

Digital Health Digital Therapeutics Early Payer Dialogue HTA HTA Process Pricing

Share this article

Related articles

White Paper
26.07.2026
Conflict-of-interest management rules and implicat...

Executive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...

Read more
Webinar
22.07.2026
Design Once, Adapt Smartly Aligning NICE and JCA e...

As NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch